TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17970879

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate 300 mg q.i.d., lansoprazole 30 mg b.i.d., tetracycline 500 mg q.i.d., metronidazole 500 mg t.i.d. (BLTM group) for 14 days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d., clarithromycin 500 mg b.i.d. (LAC group) for 14 days
Number of subjects: 240
Study: 15173777

Group type: EXPERIMENTAL
Intervention: Dipyridamole administration
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (age-matched patients with normal perfusion and normal T1-201 lung uptake)
Number of subjects: 18
Study: 11730781

Group type: EXPERIMENTAL
Intervention: Artemether
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined treatment with artemether and praziquantel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 0
Study: 9559241

Group type: EXPERIMENTAL
Intervention: Supported employment programs
Number of subjects: 63
Study: 7909912

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg.kg‐1 body weight) administered intravenously after exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: No beta‐adrenoceptor blocker administered
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Propranolol administered during recovery from exercise
Number of subjects: 6
Study: 2885802

Group type: EXPERIMENTAL
Intervention: Erythromycin (50 mg/kg/day divided in 2 doses for 10 days)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Untreated controls (21 patients)
Number of subjects: 17
Study: 31852547

Group type: COMPARATOR
Intervention: Stepped-wedge cluster randomized trials (SW-CRTs) with delayed rollout of intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SW-CRTs
Number of subjects: 0
Study: 28945992

Group type: EXPERIMENTAL
Intervention: 2000 U of cholecalciferol daily for 4 months
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 25759545

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg/d orally
Number of subjects: 59

Group type: COMPARATOR
Intervention: LAM plus ADV (LAM 100 mg/d orally + ADV 10 mg/d orally)
Number of subjects: 59
Study: 23497779

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 101
Study: 21094030

Group type: EXPERIMENTAL
Intervention: Aspirin (50mg per day) and sanchitongshu capsule (200mg three times a day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Aspirin (50mg per day) and placebo capsule
Number of subjects: 140
Study: 19127598

Group type: EXPERIMENTAL
Intervention: Soy isoflavone supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17455121

Group type: EXPERIMENTAL
Intervention: Strength Training (ST: twice a week)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Continued Reduced Training (CRT: 3 ST sessions/2 weeks)
Number of subjects: 43
Study: 14749647

Group type: EXPERIMENTAL
Intervention: Sustained-release dinoprostone with concurrent low-dose oxytocin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Multidosing of misoprostol (25 microg every 4 hours) followed by high-dose oxytocin
Number of subjects: 151

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 151
Study: 12197993

Group type: EXPERIMENTAL
Intervention: Beef-containing (BC) diet, n = 10, 0.6 g protein.kg(‐1).d(‐1) from beef
Number of subjects: 21

Group type: COMPARATOR
Intervention: Lactoovovegetarian (LOV) diet, n = 11, 0.6 g protein.kg(‐1).d(‐1) from textured vegetable protein (soy) sources
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (LOV and BC)
Number of subjects: 21
Study: 10220834

Group type: EXPERIMENTAL
Intervention: Anti-IL-8 autoantibodies (IgG, IgM, IgA)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: High titers of anti-IL-8 antibody subclasses and complexes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Free IgA and IgA/IL-8 complexes
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Elevated IgA subclass anti-IL-8 autoantibodies
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Anti-IL-8 immune complexes
Number of subjects: 85
Study: 8560312

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 2203181

Group type: EXPERIMENTAL
Intervention: 5 mg natamycin by nebuliser twice daily for one year
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo by nebuliser twice daily for one year
Number of subjects: 25
Study: 359384

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlormethiazole
Number of subjects: 60
Study: 31923066

Group type: EXPERIMENTAL
Intervention: Autologous fascial sling
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Retropubic midurethral sling
Number of subjects: 924

Group type: EXPERIMENTAL
Intervention: Transobturator midurethral sling
Number of subjects: 924

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 924
Study: 30611275

Group type: EXPERIMENTAL
Intervention: Pycnogenol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (CDRI08)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Neuroimaging techniques (Proton magnetic resonance spectroscopy, resting state functional connectivity, arterial spin labelled perfusion)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Faecal samples analysis
Number of subjects: 80
Study: 28425312

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of PNU-120596 (8 µg/kg, 15 min before surgery)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of PNU-120596
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of K+‐Cl‐ cotransporter‐2 inhibitor VU0240551
Number of subjects: 0
Study: 25824475

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) performed three times a week
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham irradiation (Control)
Number of subjects: 30
Study: 23594421

Group type: EXPERIMENTAL
Intervention: New hearing aid
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional hearing aid
Number of subjects: 16
Study: 21123030

Group type: COMPARATOR
Intervention: Dental maturation indices (Nolla and Demirjian)
Number of subjects: 155
Study: 19657730

Group type: EXPERIMENTAL
Intervention: Yoga lifestyle intervention group (n = 15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Yoga and meditation only group (n = 15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No-practice control group (n = 15)
Number of subjects: 45
Study: 17258587

Group type: EXPERIMENTAL
Intervention: Aortic side-biting clamp
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Enclose II device
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Heartstring II device
Number of subjects: 42
Study: 15493396

Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 grams taken twice on the day of dental treatment and 1 g taken twice the next day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 125
Study: 11189690

Group type: EXPERIMENTAL
Intervention: Quality control procedures for cancer screening tests (digital rectal examination, ovarian palpation examination, transvaginal ultrasound, chest X-ray, flexible sigmoidoscopy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality assurance plan developed by PLCO quality assurance subcommittee
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Periodic data analyses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procedures for duplicating examinations
Number of subjects: 0
Study: 9194104

Group type: EXPERIMENTAL
Intervention: Cefpodoxime-proxetil
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 364

Group type: COMPARATOR
Intervention: Cefpodoxime-proxetil or Amoxicillin-clavulanate
Number of subjects: 364
Study: 1347336

Group type: EXPERIMENTAL
Intervention: M‐CH (50 mg mitomycin intraoperatively)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no anticancer prophylaxis)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: M‐CH
Number of subjects: 50
Study: 3912787

Group type: EXPERIMENTAL
Intervention: Progressive relaxation therapy during a 3-week interval
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham treatment followed by progressive relaxation therapy
Number of subjects: 8
Study: 31568636

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control condition)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Patient satisfaction
Number of subjects: 10
Study: 31939369

Group type: EXPERIMENTAL
Intervention: Kedo‐S rotary file system
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: K3 rotary file system
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Hand K‐file
Number of subjects: 45
Study: 28902590

Group type: EXPERIMENTAL
Intervention: PFO closure
Number of subjects: 980

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 980
Study: 24233255

Group type: EXPERIMENTAL
Intervention: Prebiotics enriched formula containing dietary oligosaccharides (scGOS/lcFOS) at a concentration of 0.8 g/100 ml
Number of subjects: 167

Group type: COMPARATOR
Intervention: Common preterm formula
Number of subjects: 167
Study: 22660441

Group type: EXPERIMENTAL
Intervention: Fimasartan (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fimasartan (daily for 30 days)
Number of subjects: 24
Study: 21109025

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 712

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study: 20030830

Group type: EXPERIMENTAL
Intervention: Exercise tolerance testing followed by coronary angiography and treatment (percutaneous stenting or surgery) if positive results are found.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best medical/behavioral therapy offered to the exercise testing group.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical/behavioral therapy offered to the control group (regular follow-up at diabetes outpatient services).
Number of subjects: 0
Study: 17302724

Group type: EXPERIMENTAL
Intervention: Right atrial pacing
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Biatrial pacing
Number of subjects: 240

Group type: COMPARATOR
Intervention: No pacing (control group)
Number of subjects: 240
Study: 15010898

Group type: EXPERIMENTAL
Intervention: Ball approach speed of 1 m/s, 1.5 m/s, and 2 m/s with No-Goal impact requirement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ball approach speed with Near-Goal impact requirement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ball approach speed with Far-Goal impact requirement
Number of subjects: 0
Study: 11401117

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin (GTN)
Number of subjects: 60
Study: 9455667

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 227

Group type: COMPARATOR
Intervention: Operative treatment (segmental fusion)
Number of subjects: 227
Study: 8399698

Group type: EXPERIMENTAL
Intervention: Request to explain refusal to participate
Number of subjects: 1240

Group type: COMPARATOR
Intervention: Control group (no request to explain refusal)
Number of subjects: 1240
Study: 3533337

Group type: EXPERIMENTAL
Intervention: Ticlopidine 250 mg twice daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 30
Study: 2646131

Group type: EXPERIMENTAL
Intervention: Combined treatment of enuresis alarm and 20 micrograms intranasal desmopressin
Number of subjects: 28

Group type: COMPARATOR
Intervention: Alarm and placebo
Number of subjects: 28
Study: 31654782

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiation therapy (PMRT)
Number of subjects: 1633

Group type: COMPARATOR
Intervention: No PMRT
Number of subjects: 1633
Study: 31060540

Group type: EXPERIMENTAL
Intervention: Theory-based physical education intervention programme supporting autonomy, competence, and relatedness
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 600
Study: 28372680

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (intrathecal 0.5% hyperbaric bupivacaine 12.5 mg and 25 μg fentanyl)
Number of subjects: 60

Group type: COMPARATOR
Intervention: General anesthesia (intravenous analgesia, propofol, and rocuronium followed by endotracheal intubation)
Number of subjects: 60
Study: 26148612

Group type: EXPERIMENTAL
Intervention: Taurine supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23271674

Group type: EXPERIMENTAL
Intervention: Immediate empirical therapy with voriconazole
Number of subjects: 147

Group type: COMPARATOR
Intervention: Deferred therapy (placebo)
Number of subjects: 147
Study: 21702936

Group type: EXPERIMENTAL
Intervention: Brief Infant-Toddler Social and Emotional Assessment (BITSEA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 31
Study: 17926205

Group type: EXPERIMENTAL
Intervention: Non‐anaesthetic gel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Anaesthetic gel (Instillagel)
Number of subjects: 51
Study: 16935112

Group type: EXPERIMENTAL
Intervention: Mitral valve surgery with CorCap cardiac support device
Number of subjects: 193

Group type: COMPARATOR
Intervention: Mitral valve surgery alone (control)
Number of subjects: 193
Study: 12632705

Group type: EXPERIMENTAL
Intervention: Individualized 78‐item report card based on outpatient record audits
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no report cards)
Number of subjects: 44
Study: 10683002

Group type: EXPERIMENTAL
Intervention: Radiotherapy (50 Gy in 5 weeks to the whole breast)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 1010
Study: 9561593

Group type: EXPERIMENTAL
Intervention: artesunate 600 mg over 2 days and mefloquine 1,250 mg in divided doses
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: artemether 640 mg over 2 days and mefloquine 1,250 mg in divided doses
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: artesunate alone 700 mg over 5 days
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: artemether alone 800 mg over 5 days
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: quinine plus tetracycline for 7 days
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: mefloquine 1,250 mg in divided doses
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: artesunate 600 mg over 2 days and mefloquine 750 mg
Number of subjects: 394
Study: 1529904

Group type: EXPERIMENTAL
Intervention: Flecainide (300 mg/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Propafenone (900 mg/day)
Number of subjects: 34
Study: 3872627

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg in a single intramuscular dose
Number of subjects: 54

Group type: COMPARATOR
Intervention: Trimethoprim 160 mg-800 mg of sulfamethoxazole orally twice daily for 7 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 54

Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 54
Study: 29243408

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chlorine dioxide (ClO2)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (KNO3)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Sodium fluoride (NaF)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Amine fluoride (AmF)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 105
Study: 27788310

Group type: EXPERIMENTAL
Intervention: Dose-increment group (olanzapine doubled to 20 mg/d or risperidone doubled to 6 mg/d)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Continuation group (olanzapine 10 mg/d or risperidone 3 mg/d)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Dose-increment group
Number of subjects: 103

Group type: COMPARATOR
Intervention: Continuation group
Number of subjects: 103
Study: 26688983

Group type: EXPERIMENTAL
Intervention: Extraction of the deciduous canine (extraction group, EG)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Non-extraction (control group, CG)
Number of subjects: 67
Study: 23365557

Group type: EXPERIMENTAL
Intervention: Exenatide 10 μg twice daily (EX10BID)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg once daily (LIR1.2)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo or active comparator
Number of subjects: 35
Study: 20873080

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training at moderate intensity (60% of maximal effort) once a week for 12 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Normal lifestyle (control group)
Number of subjects: 37
Study: 18955428

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (Ai Chi and Halliwick methods)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Conventional therapy (gym exercises)
Number of subjects: 25
Study: 16193899

Group type: EXPERIMENTAL
Intervention: Energy conservation course
Number of subjects: 169

Group type: COMPARATOR
Intervention: Delayed control group
Number of subjects: 169
Study: 11426917

Group type: EXPERIMENTAL
Intervention: Montelukast, Zafirlukast, Zileuton (antileukotriene agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antileukotriene agents in combination with low-dose or high-dose corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antileukotriene agents
Number of subjects: 0
Study: 9868650

Group type: EXPERIMENTAL
Intervention: Rifabutin, Ethambutol, and Clarithromycin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ethambutol
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 86
Study: 8124838

Group type: EXPERIMENTAL
Intervention: Intensive multifactor risk reduction
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 2666120

Group type: EXPERIMENTAL
Intervention: Cinromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 171780

Group type: EXPERIMENTAL
Intervention: Tinidazole 800 mg t.d.s. for 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 10

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 10
Study: 31825067

Group type: EXPERIMENTAL
Intervention: Continuous energy restriction (CER) - 25% daily energy restriction
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) - alternating ad libitum and 75% energy restriction days
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both interventions (CER and IER)
Number of subjects: 46
Study: 30830659

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 724

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 724
Study: 27515097

Group type: EXPERIMENTAL
Intervention: LAS41008
Number of subjects: 671

Group type: COMPARATOR
Intervention: Fumaderm®
Number of subjects: 671
Study: 26384978

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) - Coping Cat
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 64
Study: 25308408

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nitroglycerin
Number of subjects: 40
Study: 22147286

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous ibuprofen
Number of subjects: 80
Study: 19570752

Group type: EXPERIMENTAL
Intervention: auto-adjusting continuous positive airway pressure (auto-CPAP) with supplemental oxygen if required
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study: 17632222

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Clozapine and Olanzapine
Number of subjects: 112

Group type: COMPARATOR
Intervention: Risperidone and Sulpiride
Number of subjects: 112
Study: 15103438

Group type: EXPERIMENTAL
Intervention: fosfluconazole (1000 mg bolus intravenous injection)
Number of subjects: 24

Group type: COMPARATOR
Intervention: fluconazole (800 mg intravenous infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: fosfluconazole
Number of subjects: 24

Group type: COMPARATOR
Intervention: fluconazole
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: fosfluconazole and fluconazole
Number of subjects: 24
Study: 12234028

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg preoperatively for 10-14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine premedication
Number of subjects: 30
Study: 9638548

Group type: EXPERIMENTAL
Intervention: Injectable dexamethasone sodium phosphate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (normal sterile saline)
Number of subjects: 42
Study: 8088258

Group type: EXPERIMENTAL
Intervention: Gabapentin (Neurontin) as add-on therapy at dosages of 600-2400 mg/day
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Gabapentin (Neurontin) as add-on therapy
Number of subjects: 240
Study: 2776093

Group type: EXPERIMENTAL
Intervention: oral solution
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: film‐coated tablets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: enteric‐coated tablets
Number of subjects: 10
Study: 1100188

Group type: EXPERIMENTAL
Intervention: Reinforced Steristrip skin closures
Number of subjects: 512

Group type: COMPARATOR
Intervention: Interrupted silk sutures
Number of subjects: 512
Study: 30383097

Group type: EXPERIMENTAL
Intervention: Young fresh frozen plasma (yFFP) from male donors, 1 unit (approximately 250 mL) infused once weekly for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (placebo), 250 mL infused once weekly for 4 weeks
Number of subjects: 18
Study: 28294641

Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0

Group type: COMPARATOR
Intervention: liraglutide added to basal insulin
Number of subjects: 0